Non-small cell lung cancer · line 1 · Pembrolizumab monotherapy (NSCLC PD-L1 ≥50%, driver-negative, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PEMBRO-MONO-NSCLC |
| ID | IND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFIC |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track for label-strict pembrolizumab 1L eligibility (22C3 clone-specific). Companion to standard-track IND-NSCLC-PDL1-HIGH-MET-1L (any TPS clone). KEYNOTE-024 evidence base shared; this Indication adds clone-specificity per W7f scope.
Used By
No reverse references found in the YAML corpus.